1. No longer recruiting "Clinical Trials to Enhance Elders' Oral Health" ("TEETH") 2. Completed A "Pre-Enrollment" Protocol for HIV-Infected Adolescents 3. Recruiting The "Reach For Health" Program: Delaying Sexual Activity in Children 4. Recruiting "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk 5. No longer recruiting (1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients who Receive Neurotoxic Therapy 6. Completed (PET) Imaging in the Management of Patients with Solitary Pulmonary Nodules 7. Completed (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC 8. Completed 1-Octanol to Treat Essential Tremor 9. Completed 1-Octanol to Treat Essential Tremor 10. No longer recruiting A 1-Year Study of an Investigational Drug in Obese Patients 11. Suspended 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma 12. No longer recruiting 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer 13. Completed 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors 14. No longer recruiting 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy. 15. Completed 12 week,comparing safety of HMR1964 & insulin aspart used in continuous subcutaneous infusion in type 1 diabetes. 16. Recruiting 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder 17. No longer recruiting A 12-week, multicenter, safety and dose-ranging study of 3 oral doses of TCH346 in patients with Amyotrophic Lateral Sclerosis 18. Recruiting 131MIBG to Treat Malignant Pheochromocytoma 19. Recruiting A 14-day study of Racivir when used in combination in HIV-Infected Males 20. Recruiting 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma 21. Recruiting 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors 22. Recruiting 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas 23. Recruiting 17-DMAG to Treat Patients with Solid Tumors or Lymphomas 24. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor 25. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma 26. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer 27. Not yet recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer 28. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery 29. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma 30. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer 31. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors 32. Recruiting 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia 33. Recruiting 17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease 34. Recruiting 2 doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting 35. Recruiting 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting 36. No longer recruiting 2-Methoxyestradiol (2-ME2) to Treat Solid Tumor Cancers 37. Recruiting 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors 38. No longer recruiting A 2-Year Study of an Investigational Drug in Obese Patients 39. Recruiting A 20-week study of a new treatment for men with Benign Prostatic Hyperplasia (BPH). 40. Recruiting A 24 Week Study of Daily Oral Investigational Drug vs Placebo in Patients with Asthma 41. Completed A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS 42. No longer recruiting 3 Different Dose Levels of CCI-779 in Subjects with Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy 43. Recruiting 3 Fixed Dosages of Extended Release OROS Paliperidone and Olanzapine in the Treatment of Subjects with Schizophrenia 44. No longer recruiting 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors 45. Not yet recruiting 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer 46. No longer recruiting 3-AP and Cytarabine in Treating Patients With Hematologic Cancer 47. Recruiting 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors 48. Recruiting 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer 49. Recruiting 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer 50. Recruiting 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
